Mealey's (June 26, 2019, 1:39 PM EDT) -- ALEXANDRIA, Va. — In a June 25 filing with the Patent Trial and Appeal Board, Sanofi-Aventis Deutschland GMBH pointed to the “overwhelming” commercial success of its “LANTUS® SoloSTAR®” pen injector as evidence of non-obviousness (Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GMBH, No. IPR2018-01678, PTAB)....